Skip to main content
Premium Trial:

Request an Annual Quote

PlaqueTec Enrolling UK Patients in Blood-Based Biomarker Study for Coronary Artery Disease

NEW YORK – PlaqueTec on Wednesday said it has received approval from the UK Medicines and Healthcare products Regulatory Agency to continue recruiting for a trial using its blood sampling system to better understand coronary artery disease (CAD) and biomarkers involved in disease progression toward heart attack.

The Cambridge, UK-based firm has so far enrolled 10 patients with CAD into its BioPattern trial, through which investigators will use PlaqueTec's Liquid Biopsy System to collect blood samples and analyze numerous proteins and biomolecules. The firm's process includes a multiomic approach and plaque imaging to analyze samples.

With the new approval from the UK regulator, the company is aiming to enroll 300 patients scheduled for a coronary angiogram.

PlaqueTec hopes that findings from the trial will establish safety and functionality of the liquid biopsy system and fuel understanding into the pathobiology of CAD and how it varies between patients. The company also plans to use findings to create a data platform to stratify patients with specific disease endotypes and inform development of new therapies.

PlaqueTec is recruiting participants at four UK National Health Service specialty cardiac centers with plans to add four more sites.